NeurologyLive® Friday 5 — December 16, 2022

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 16, 2022.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: First-Ever Genetic Links Found in Progressive Multifocal Leukoencephalopathy

For the first time, researchers have identified genetic variants that are associated with an increased risk of progressive multifocal leukoencephalopathy, a rare and often lethal brain disorder that develops in a wide range of immunosuppressed groups and can occur as a serious adverse event from exposure to immunosuppressives.

First-Ever Genetic Links Found in Progressive Multifocal Leukoencephalopathy

2: Mind Moments® Episode 79: A New Monoclonal for Alzheimer Disease

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Marwan Sabbagh, MD, FAAN, who joined the show to discuss the clinical trial results for lecanemab (Biogen/Eisai) that were presented at the Clinical Trials on Alzheimer’s Disease meeting in San Francisco, the drug’s overall efficacy profile, as well safety information and the rates of ARIA, and more. [LISTEN TIME: 21 minutes]

Assessing Response to Insomnia Treatment

3: NeuroVoices: Susan Abushakra, MD, on the Potential Role of ALZ-801 Within the Alzheimer Treatment Landscape

In the latest edition of our in-depth Q&A series, the chief medical officer of Alzheon detailed the efficacy, safety, and potential of ALZ-801, an investigational anti-amyloid therapy being assessed in high-risk individuals with early Alzheimer disease.

NeuroVoices: Susan Abushakra, MD, on the Potential Role of ALZ-801 Within the Alzheimer Treatment Landscape

4: Future Implications of New Framework to Characterize Multiple Sclerosis: Ruth Ann Marrie, MD, PhD, FRCPC

In a conversation with NeurologyLive®, the professor of medicine at the University of Manitoba detailed the implications of a new paper suggesting changes to the characterization of MS phenotypes and how it might impact previously approved therapies. [WATCH TIME: 3 minutes]

Future Implications of New Framework to Characterize Multiple Sclerosis: Ruth Ann Marrie, MD, PhD, FRCPC

5: Peers & Perspectives: Advice for Advanced Practice Providers in Managing Sleep Disorders

In the final episode of this NeurologyLive® series, advanced practice providers Wendy L. Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; and Debra Davis, CRNP, share their final pearls of wisdom with their colleagues as it pertains to the management of sleep disorders.

Advice for Advanced Practice Providers in Managing Sleep Disorders

—————————————————

Related Videos
View All
Related Content
© 2023 MJH Life Sciences

All rights reserved.